Evidence map›Paper›PMID 28053101›Full record

ArticleJournal of virology2017

Generation of a Genetically Stable High-Fidelity Influenza Vaccine Strain.

Tadasuke Naito, Kotaro Mori, Hiroshi Ushirogawa, Naoki Takizawa, Eri Nobusawa, Takato Odagiri, Masato Tashiro, Ryosuke L Ohniwa, Kyosuke Nagata, Mineki Saito

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Tadasuke NaitoDepartment of Microbiology, Kawasaki Medical School, Okayama, Japan tadanaito@med.kawasaki-m.ac.jp knagata@md.tsukuba.ac.jp.
Kotaro MoriLaboratory of Virology, Institute of Microbial Chemistry, Tokyo, Japan.
Hiroshi UshirogawaDepartment of Microbiology, Kawasaki Medical School, Okayama, Japan.
Naoki TakizawaLaboratory of Virology, Institute of Microbial Chemistry, Tokyo, Japan.
Eri NobusawaInfluenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Takato OdagiriInfluenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Masato TashiroInfluenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Ryosuke L OhniwaFaculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Kyosuke NagataFaculty of Medicine, University of Tsukuba, Ibaraki, Japan tadanaito@med.kawasaki-m.ac.jp knagata@md.tsukuba.ac.jp.
Mineki SaitoDepartment of Microbiology, Kawasaki Medical School, Okayama, Japan.
Kawasaki Medical School · JPNational Institute of Infectious Diseases · JPUniversity of Tsukuba · JPMicrobial Chemistry Research Foundation · JPNational Taiwan University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaccination is considered the most effective preventive means for influenza control. The development of a master virus with high growth and genetic stability, which may be used for the preparation of vaccine viruses by gene reassortment, is crucial for the enhancement of vaccine performance and efficiency of production. Here, we describe the generation of a high-fidelity and high-growth influenza vaccine master virus strain with a single V43I amino acid change in the PB1 polymerase of the high-growth A/Puerto Rico/8/1934 (PR8) master virus. The PB1-V43I mutation was introduced to increase replication fidelity in order to design an H1N1 vaccine strain with a low error rate. The PR8-PB1-V43I virus exhibited good replication compared with that of the parent PR8 virus. In order to compare the efficiency of egg adaptation and the occurrence of gene mutations leading to antigenic alterations, we constructed 6:2 genetic reassortant viruses between the A(H1N1)pdm09 and the PR8-PB1-V43I viruses; hemagglutinin (HA) and neuraminidase (NA) were from the A(H1N1)pdm09 virus, and the other genes were from the PR8 virus. Mutations responsible for egg adaptation mutations occurred in the HA of the PB1-V43I reassortant virus during serial egg passages; however, in contrast, antigenic mutations were introduced into the HA gene of the 6:2 reassortant virus possessing the wild-type PB1. This study shows that the mutant PR8 virus possessing the PB1 polymerase with the V43I substitution may be utilized as a master virus for the generation of high-growth vaccine viruses with high polymerase fidelity, low error rates of gene replication, and reduced antigenic diversity during virus propagation in eggs for vaccine production.

Indexed as

Amino Acid SubstitutionAntigens, ViralInfluenza A virusInfluenza VaccinesPoint MutationReassortant VirusesTechnology, PharmaceuticalViral ProteinsVirologyAntigens, ViralInfluenza Vaccinesinfluenza virus polymerase basic protein 1Viral Proteinsfidelityinfluenzainfluenza vaccinesreverse genetic analysisRNA polymerases

Identifiers

PMID28053101
PMCPMC5331824
OpenAlexW2568529450

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.